Japan's Shionogi brings treatment for Gram-Negative Bacterial Infections in Singapore and Malaysia
Singapore, Nov. 16 -- Japan-based pharma firm Shionogi has entered into a license agreement with Link Healthcare, headquartered in Singapore, for the development and market development of cefiderocol, a treatment for Gram-negative bacterial infections discovered by Shionogi, in Singapore and Malaysia.
In March 2025, Shionogi entered into a license agreement with Link Medical Products Pty Ltd, which, like Link, is part of Clinigen, for the development and market development of cefiderocol in Australia and New Zealand, and the companies have since been collaborating to make cefiderocol available in these markets. Through this new Agreement, Shionogi is expanding its collaboration with Clinigen to Singapore and Malaysia, with the aim of mak...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.